Lynparza has been approved for BRCA-mutated advanced ovarian cancer
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
List view / Grid view
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
A multi-company system to improve traceability of pharmaceutical products is newly supported by the FDA.
In this issue we explore reasons behind critical key drug shortages in the EU, whether viability methods effectively detect all viable organisms and how companies can future-proof their digital technologies ahead of Brexit. Also included are articles on higher order protein structure, FMD compliance and Raman spectroscopy.
A study has predicted that the global biopharmaceutical contract manufacturing market will grow by 10.6 percent from 2017 to 2027.
A data analyst has reported that the current US-China trade war will give India chance to increase their pharmaceutical presence.
Catalyst Pharmaceuticals Inc has sued the FDA to challenge the recent approval of a lower-cost rival drug.
Luxembourg and the Netherlands have been included in the mutual recognition agreement between the EU and the FDA in the US.
The Parenteral Drug Association (PDA) is excited to host its 4th Annual European Meeting.
Decreased supply of anti-rabies vaccines (ARVs) in Delhi causes outbreak of the disease.
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
Lubricants have a far more wide-reaching impact on the characteristics of the finished tablet than merely easing their means of production. A study was carried out to investigate precisely what those effects were.
A research team from Scripps Research Translational Institute has published revealing figures in relation to drug prices in the US.
New briefing documents provide policy recommendations to help the EU tackle high medicines prices brought about by market monopolies.
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
GlaxoSmithKline (GSK) has been given Chinese approval for its shingles vaccine.